Committee Chair Succession & Director Declaration

27 February 2023

Centrica plc

('Centrica' or 'the Company')

COMMITTEE CHAIR SUCCESSION AND DIRECTOR DECLARATION

In accordance with Listing Rule 9.6.11, Centrica today announces that Nathan Bostock will succeed Kevin O'Byrne as Chair of the Company's Audit and Risk Committee with effect from 1 March 2023. 

In addition, further to the announcement today by International Flavors & Fragrances Inc. ('IFF') and in accordance with Listing Rule 9.6.14R (2), Centrica further announces that Kevin O'Byrne has been appointed as a Non-Executive Director of IFF, listed on the NYSE, with effect from 10 March 2023.

Kevin O'Byrne has served as Chair of the Company's Audit and Risk Committee for approaching 4 years and will remain the Company's Senior Independent Director.

Nathan Bostock was appointed a Non-Executive Director of the Company on 9 May 2022 and has been a member of the Company's Audit and Risk Committee since that date. 

ENDS

Enquiries:

Investors and Analysts
T: 01753 494900
E: [email protected]

Media
T: 01784 843000
E: [email protected]

Centrica plc is listed on the London Stock Exchange (CNA)
Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD

Registered in England & Wales number: 3033654
Legal Entity Identifier number: E26EDV109X6EEPBKVH76
ISIN number: GB00B033F229